Harvard Bioscience (HBIO) Misses Q2 EPS by 2c, misses on revenue, offers guidance

Harvard Bioscience (NASDAQ: HBIO) reported Q2 EPS of $0.04, $0.02 worse than the analyst estimate of $0.06. Revenue for the quarter came in at $28.8 million versus the consensus estimate of $29.63 million.

2023 Guidance

The company expect revenues of approximately $116 million to $120 million for the full year 2023. This expected growth anticipates an approximate 4 percentage point headwind from discontinued products. For the year 2023, we expect gross margins of approximately 60% and adjusted EBITDA margins in the 15% to 17% range.

For earnings history and earnings-related data on Harvard Bioscience (HBIO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c